Jefferies raised the firm’s price target on AxoGen (AXGN) to $29 from $25 and keeps a Buy rating on the shares after Q3 sales beat consensus by about 6% and the company raised FY25 sales growth guidance to at least 19% year-over-year. The Q3 report “showed solid execution all around,” the analyst tells investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXGN: